Provenge Approval History
- FDA approved: Yes (First approved April 29th, 2010)
- Brand name: Provenge
- Generic name: sipuleucel-T
- Dosage form: Suspension for Intravenous Infusion
- Previous name: APC8015
- Company: Dendreon Corporation
- Treatment for: Prostate Cancer
Provenge (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
Development History and FDA Approval Process for Provenge
| Date | Article |
|---|
| Apr 29, 2010 |  FDA Approves Provenge - a Cellular Immunotherapy for Men With Advanced Prostate Cancer |
| Nov 22, 2009 | Dendreon Receives FDA Acknowledgement of Complete Response for Provenge |
| Nov 2, 2009 | Dendreon Completes Submission of Biologics License Application for Provenge |
| Jul 30, 2007 | D.C. Denies Prostate Cancer Vaccine, Provenge: Dendreon (WA) Not
FDA To Blame |
| Jun 1, 2007 | Prostate Cancer Patients, Survivors and Advocates Assemble on
Capitol Hill to Rally against FDA's Non Approval of Provenge |
| May 31, 2007 | Dendreon Announces FDA Confirms Data Required for Provenge
Licensure |
| May 9, 2007 | Dendreon Receives Complete Response Letter From FDA for Provenge
Biologics License Application |
| Mar 30, 2007 | Dendreon Announces FDA Advisory Committee Reviewed Provenge for
Hormone Refractory Prostate Cancer |
| Mar 27, 2007 | Dendreon to Hold Post Advisory Committee Conference Call for Provenge |
| Mar 1, 2007 | Dendreon Announces FDA's Cellular, Tissue and Gene Therapies Advisory Committee to Review Provenge for the Treatment of Asymptomatic, Metastatic, Androgen-Independent Prostate Cancer |
| Jan 16, 2007 | Dendreon’s Provenge Granted FDA Priority Review |
| Nov 13, 2006 | Dendreon Completes Submission of Biologics License Application to FDA for Provenge in Hormone Refractory Prostate Cancer |
| Aug 24, 2006 | Dendreon Submits Clinical and Non-Clinical Sections of Rolling BLA to FDA for Provenge |
| Sep 14, 2005 | Dendreon Announces Plans to Submit BLA |
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.
